Zepbound Cost in Maryland 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Zepbound Actually Cost in Maryland Right Now?

The Eli Lilly list price for Zepbound is $1,059.12 per month across all dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) as of 2026. Maryland retail pharmacies, including CVS, Rite Aid, Giant, and Walgreens locations throughout Baltimore, Bethesda, Rockville, and Annapolis, price it at or near that list price for uninsured cash-pay patients. Zepbound FDA prescribing information confirms the product is available as a single-dose autoinjector pen.

Why the Price Does Not Vary Much by Dose

Unlike some medications that carry dose-dependent pricing, Eli Lilly set a flat monthly price for Zepbound regardless of strength. A patient on 2.5 mg pays the same list price as a patient on 15 mg. That design choice simplifies titration cost planning, though it does nothing to reduce the absolute dollar burden.

GoodRx and Discount Card Estimates in Maryland

Third-party discount platforms list Zepbound between $980 and $1,059 at Maryland pharmacies after coupon application in 2026. Those figures apply only to patients paying entirely out of pocket and cannot be combined with any federal or state insurance benefit. The FDA drug shortage database notes that certain Zepbound strengths experienced intermittent national supply tightness through mid-2025, so local availability at specific Maryland pharmacies should be confirmed before relying on any one location.

Does Maryland Medicaid Cover Zepbound?

Maryland Medicaid (Maryland Medical Assistance) covers tirzepatide (Zepbound) for chronic weight management with a prior authorization (PA) requirement as of 2026. Coverage applies to adult enrollees who meet body mass index criteria consistent with FDA labeling: BMI of 30 kg/m or higher, or BMI of 27 kg/m or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy endorses tirzepatide as a first-line pharmacological option for adults meeting those criteria.

Prior Authorization Criteria for Maryland Medicaid

Maryland's PA process typically requires documentation of:

• A confirmed BMI at or above the applicable threshold, measured within the past 12 months
• At least one prior documented attempt at lifestyle modification (diet and/or exercise program of at least 3 months)
• Absence of contraindications listed in the FDA label, including personal or family history of medullary thyroid carcinoma or MEN2

Clinicians prescribing through telehealth platforms serving Maryland Medicaid enrollees report PA approval timelines of 5 to 14 business days. Denials can be appealed; the Maryland Insurance Administration oversees the appeals process for Medicaid managed-care plans operating in the state.

What Maryland Medicaid Covers After Approval

Once PA is granted, Maryland Medicaid enrollees typically pay $0 to $3 per fill under standard cost-sharing tiers. The actual copay depends on the specific managed-care organization (MCO) the enrollee is assigned to: CareFirst BlueCross BlueShield, UnitedHealthcare Community Plan, Aetna Better Health of Maryland, and Maryland Physicians Care each operate under Maryland Medicaid with their own formularies. Patients should confirm Zepbound's tier placement directly with their assigned MCO before the first fill.

How Effective Is Zepbound? The Clinical Data Behind the Price

Spending more than $1,000 per month requires confidence in the drug's efficacy. That confidence is grounded in well-powered trial data.

SURMOUNT-1 Results

SURMOUNT-1 enrolled 2,539 adults without diabetes who had a BMI of 30 kg/m or higher (or 27 kg/m or higher with a weight-related comorbidity). Participants received tirzepatide 5 mg, 10 mg, or 15 mg weekly or placebo for 72 weeks. The 15 mg dose arm produced a mean body weight reduction of 20.9% versus 3.1% for placebo (P<0.001). Jastreboff et al., NEJM 2022 published the full results. That degree of weight loss is comparable to outcomes historically achieved only with bariatric surgery in short-term follow-up.

SURMOUNT-2 and the Diabetes Subpopulation

SURMOUNT-2 studied 938 adults with type 2 diabetes and obesity. At 72 weeks, the 15 mg arm achieved 15.7% mean body weight loss versus 3.3% for placebo (P<0.001). Jastreboff et al., Lancet 2023 reported these findings, which supported the FDA's approval of Zepbound for chronic weight management irrespective of diabetes status. The trial enrolled sites across 13 countries; US participants with comorbid hypertension showed particularly large waist-circumference reductions.

Cardiovascular Benefit Signal

The SURMOUNT-MMO trial (ongoing as of early 2026) is specifically powered to assess major adverse cardiovascular events (MACE) in adults with obesity who do not have diabetes. Interim observational data from ClinicalTrials.gov NCT05556512 suggest lower rates of incident hypertension in participants on 10 mg and 15 mg doses compared with placebo at 36 weeks, though the trial is not yet fully reported. The American Heart Association's 2023 scientific statement on obesity and cardiovascular disease identifies GLP-1-based therapies as having a favorable cardiovascular risk profile in patients with established cardiometabolic disease.

Is Compounded Tirzepatide Legal in Maryland?

Compounded tirzepatide prepared by a licensed 503A compounding pharmacy is legal to dispense in Maryland as of early 2026, subject to specific regulatory conditions. FDA guidance on compounding allows 503A pharmacies to compound copies of FDA-approved drugs only when the drug appears on the FDA drug shortage list or when a prescriber documents a specific medical need that the commercial product cannot meet.

503A vs. 503B: What Maryland Patients Need to Know

A 503A pharmacy compounds for individual patients based on a valid prescription from a licensed prescriber. A 503B outsourcing facility produces larger batches without patient-specific prescriptions. Maryland patients receiving compounded tirzepatide through a telehealth platform should confirm that the compounding pharmacy holds a valid Maryland Board of Pharmacy registration. The Maryland Board of Pharmacy publishes a searchable licensee database.

Compounded tirzepatide from Maryland-registered 503A pharmacies was running approximately $249 per month in early 2026 for a typical maintenance dose. That represents a 76% discount relative to the Eli Lilly list price. The trade-off: compounded products are not FDA-approved and have not undergone the same manufacturing consistency review as Zepbound.

FDA's Evolving Position on Tirzepatide Compounding

The FDA removed tirzepatide from its drug shortage list in October 2024, which legally restricts 503A and 503B pharmacies from compounding copies of Zepbound or Mounjaro for most patients. As of early 2026, FDA enforcement actions against 503B facilities have escalated. FDA's March 2024 compounding update warned consumers about unapproved compounded tirzepatide products. Maryland 503A pharmacies may still compound for patients with a documented clinical justification (for example, a need for a dose strength not commercially available), but the legal window has narrowed significantly. Patients considering compounded tirzepatide in Maryland should consult a prescriber and confirm the pharmacy's current regulatory status before ordering.

Which Private Insurance Plans Cover Zepbound in Maryland?

Commercial insurance coverage for Zepbound in Maryland varies by plan, employer benefit design, and year. The Affordable Care Act does not mandate coverage of obesity pharmacotherapy, so coverage is entirely at the employer's or insurer's discretion.

Large Employer Plans

Large self-insured employers headquartered in Maryland (and those operating federal contracts under the DC metro area) increasingly include anti-obesity medications on formulary. CareFirst BlueCross BlueShield, the dominant commercial insurer in Maryland, covers tirzepatide for obesity on its Gold and Platinum commercial tiers as of 2026, subject to step-therapy requirements. Step therapy at CareFirst typically requires a 90-day documented trial of a lower-cost agent (often phentermine-topiramate or bupropion-naltrexone) before Zepbound is approved, unless clinical contraindications exist.

Federal Employee Health Benefits (FEHB) in Maryland

Maryland is home to a large federal workforce given its proximity to Washington, DC. FEHB plans began covering anti-obesity medications for federal employees starting January 1, 2026, following the Office of Personnel Management's directive. Federal employees in Maryland enrolled in GEHA, Blue Cross Blue Shield FEP, or Aetna FEHB plans should confirm their plan's specific Zepbound prior authorization form for obesity (separate from the diabetes indication on Mounjaro).

ACA Marketplace Plans in Maryland

Maryland Health Connection administers the ACA marketplace for the state. As of 2026, most Silver-tier marketplace plans in Maryland do not cover Zepbound for obesity, though some Gold-tier plans from CareFirst and Kaiser Permanente Mid-Atlantic do include it with PA requirements. Patients should use the formulary search tool on each carrier's website rather than relying on broker summaries, which may be outdated. The National Academy for State Health Policy's GLP-1 tracker provides state-level insurance coverage updates.

How the Eli Lilly Savings Card Works for Maryland Patients

Eli Lilly offers a savings program for commercially insured patients in Maryland that can reduce out-of-pocket cost to as low as $25 per month for a 1-month supply, or $50 for a 3-month supply (terms as of early 2026). Patients must have commercial insurance that covers Zepbound. The savings card cannot be used by patients enrolled in Medicare, Medicaid, or any other state or federal program. Eli Lilly's savings program terms specify an annual savings cap that varies by plan year; patients should confirm the current cap before assuming the $25/month rate applies to their full year of treatment.

Who Does Not Qualify

Medicare Part D enrollees in Maryland are explicitly excluded from the Lilly savings card. Medicare currently does not cover Zepbound for obesity (it covers tirzepatide as Mounjaro for type 2 diabetes only). A Maryland patient over 65 with obesity but without a diabetes diagnosis pays the full list price under Medicare unless a supplemental plan or employer retiree benefit specifically includes it.

Patient Assistance Program

Eli Lilly's Insulin Value Program site also links to its patient assistance program for uninsured or underinsured patients whose household income falls below 400% of the federal poverty level. Approved applicants may receive Zepbound at no cost. Application requires income verification and a prescriber attestation. Processing typically takes 3 to 4 weeks.

Getting Zepbound via Telehealth in Maryland

Telehealth prescribing of Zepbound is fully permitted in Maryland as of 2026. Maryland law allows clinicians licensed in the state to prescribe Schedule-uncontrolled medications (tirzepatide is not a controlled substance) via synchronous audio-video visits without a prior in-person requirement. The Maryland Telehealth Program operated by the Maryland Health Care Commission outlines applicable prescribing standards.

What a Telehealth Visit for Zepbound Should Include

A medically appropriate telehealth evaluation for Zepbound in Maryland should document:

• Measured or self-reported height and weight sufficient to calculate BMI
• Review of contraindications from the FDA label, including personal or family history of thyroid C-cell tumors
• Baseline metabolic panel and HbA1c if not available from recent lab records
• Discussion of injection technique, storage requirements (refrigerated at 36 to 46 degrees Fahrenheit), and titration schedule
• A follow-up plan at 4 and 12 weeks to assess tolerability and early weight response

The Obesity Medicine Association's 2023 clinical practice statement recommends reassessing medication appropriateness at 12 weeks: if a patient has not achieved at least 5% body weight reduction on the highest tolerated dose, the prescriber should reconsider the treatment plan.

Telehealth Platforms Active in Maryland

Multiple telehealth platforms serve Maryland ZIP codes and offer Zepbound prescribing as of 2026. Pricing through these platforms typically bundles the clinical visit fee with medication cost or charges separately. Patients should confirm whether the platform's prescriber holds an active Maryland medical license and whether the compounding pharmacy used (if applicable) holds Maryland Board of Pharmacy registration.

Comparing All Maryland Access Pathways Side by Side

| Pathway | Estimated Monthly Cost | PA Required? | Notes | |---|---|---|---| | Cash pay, retail pharmacy | ~$1,059 | No | Flat price across all doses | | Commercial insurance (CareFirst Gold) | $0, $150 copay | Yes | Step therapy may apply | | Eli Lilly savings card (commercial ins.) | $25, $50 | Yes (insurance) | Annual cap; no Medicare/Medicaid | | Maryland Medicaid | $0, $3 | Yes | MCO formulary varies | | Federal employee (FEHB, from Jan 2026) | Varies by plan | Yes | Confirm per plan | | Compounded tirzepatide (503A, MD-licensed) | ~$249 | No (Rx required) | Not FDA-approved; legal window narrowing | | Lilly patient assistance program | $0 | Yes (income docs) | <400% FPL; 3 to 4 week processing |

Side Effects and Safety Considerations Before Starting

Zepbound's most common adverse effects are gastrointestinal. In SURMOUNT-1, nausea occurred in 31.0% of patients on 15 mg versus 6.2% on placebo; vomiting in 16.4% versus 2.8%; and diarrhea in 22.7% versus 10.0% Jastreboff et al., NEJM 2022. Most GI events were mild to moderate and resolved with continued use or dose reduction. Serious adverse events included acute pancreatitis (0.2% vs. 0.2% placebo, not statistically elevated) and cholelithiasis (0.6% vs. 0.2%). The FDA label carries a Boxed Warning for thyroid C-cell tumor risk based on rodent studies; human relevance is unknown but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma. FDA's Zepbound label lists the complete contraindication and warning profile.

Injection Site and Storage Guidance

Zepbound autoinjector pens require refrigeration between 36 and 46 degrees Fahrenheit. They may be stored at room temperature (up to 86 degrees Fahrenheit) for up to 21 days if needed. Injection sites rotate weekly among the abdomen, thigh, and upper arm. CDC injection technique guidance applies general subcutaneous injection principles relevant to patient training.

Drug Interactions and Comorbidity Considerations

Tirzepatide slows gastric emptying, which may affect absorption of oral medications taken concurrently. Patients on oral contraceptives should use a non-oral backup method for 4 weeks after each dose escalation, per the Zepbound label. The American Diabetes Association's 2024 Standards of Care recommends monitoring blood glucose and adjusting concurrent diabetes medications to reduce hypoglycemia risk when initiating tirzepatide in patients already on sulfonylureas or insulin.

Maryland-Specific Clinical Context

Maryland ranks 24th among US states for adult obesity prevalence, with 34.5% of adults meeting the BMI-defined obesity threshold per the CDC's Behavioral Risk Factor Surveillance System 2023 data. Baltimore City's obesity rate exceeds the statewide average at approximately 37.2%, and Prince George's County shows similarly elevated rates correlated with income and food-access disparities. Those demographics make the cost question for Zepbound particularly consequential in Maryland: the patients with the greatest clinical need often have the least financial capacity to absorb a $1,059 monthly cash price.

The NIH National Institute of Diabetes and Digestive and Kidney Diseases weight management data shows that obesity-related annual healthcare costs in the US average $1,861 per person above non-obese baseline costs, which can be used to frame the economic argument for payer coverage of effective pharmacotherapy.